PerkinElmer's role in the historic Cassini spacecraft mission to Saturn.
New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the AlphaLISA human PD-L1 assay.
The Australian Institute of Marine Science (AIMS) is helping to sustain and restore damage to ecosystems due to a changing climate and microplastics contamination in the Great Barrier Reef.
North York General Hospital researchers have developed an Enhanced First Trimester Screen that is faster, less costly, but just as accurate as the standard Integrated Prenatal Screening protocol in detecting the risk for Down syndrome and Trisomy 18. The new test was developed with the help of PerkinElmer and is now in use in Ontario, Canada.
Eurofins Scientific worked with PerkinElmer and Environmental Sciences, Inc. to optimizes production analysis of a wide range of samples from food and liquids to pharmaceuticals built on PerkinElmer’s NexION ICP-MS and the intelligent autosampling of ESI’s SC-FAST innovation.
Using a PerkinElmer Opera Phenix Imaging System and proprietary analytic algorithms, a team of Austrian scientists developed Pharmacoscopy, a method to rapidly screen existing drugs for potential use in cancer immunotherapy.
An overview of Juniper Analytics and its quest to become a certified cannabis testing lab in Oregon with the help of PerkinElmer and the QSight® Triple Quad LC/MS/MS.
Scientist undertakes historical assessment of the Tennessee River’s water quality with the help of PerkinElmer.
Pharmaceutical services company Aptuit used two different methods to arrive at the same conclusion: PerkinElmer's NexION® ICP-MS is the best analytical instrument on the market.
Cord blood stem cells saved at birth have offered hope to families faced with life-changing medical conditions once thought untreatable, such as cerebral palsy and autism.
Powerful new Single Cell Inductively Coupled Mass Spectrometer is capable of analyzing metal nanoparticles in single cell environments, which is likely to reshape nanoparticle regulations.
With global sourcing changing the nature of the supplements industry, companies, suppliers, and regulators are turning to ICP-MS techniques to monitor the quality and purity of ingredients.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In an ovarian cancer case study, Dr. Feldman uses this instrumentation to modernize pathology.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a squamous cell carcinoma cancer case study, Dr. Fox uses the instrumentation to help develop predictive biomarkers.
PerkinElmer is serving in a central role in two EU-based consortia based projects focused on tracing the fate of nanomaterials to determine their potential toxicity and impact on air, soil, and water.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lymphoma cancer case study, Dr. Rodig uses the instrumentation to gain insight into tumor pathogenesis.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lung cancer case study, Dr. Rimm uses this instrumentation to evaluate tumor infiltrating lymphocytes.
PerkinElmer scientists in concert with colleagues from the University Hospital of Wales and Cardiff University have developed a new immunoassay screen for Duchenne Muscular Dystrophy.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a colorectal case study, Dr. Galon uses this instrumentation to uncover more details about cancer and the immune system.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a breast cancer case study, Dr. Rimm uses this instrumentation in her immune-oncology research.
Two years after forming a strategic collaboration AMRI and PerkinElmer are helping to eliminate research and clinical data silos and advance precision medicine.
An overview of India's ambitious National Optical Fiber Network and the roles Jain Irrigation Systems, Ltd., and PerkinElmer are playing as one of the world’s largest fiber optic networks become a reality.
Research at Institut Pasteur de Lille using PerkinElmer’s Opera® High-Content Screening System and Acapella® Image Analysis Software contributes substantial new information to our understanding of M. tuberculosis.
For over 40 years PerkinElmer has been the official instrument supplier and fuel certification sponsor for the INDYCAR® Series.
Cancer researchers now can visualize more of a tumor than ever before using PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions. In a melanoma case study, Dr. Tumeh uses this instrumentation to develop biomarkers in his cancer immunology research.
To help global regulators identify, quantify, and qualify microplastics in the waterways around the globe researchers are deploying PerkinElmer's infrared (IR) spectroscopy instruments.
Using the Attivo and SciBite TERMite platforms, researchers can now unlock the value of unstructured data found in electronic medical records, to reveal medical discoveries that would otherwise be lost in too much data.
PerkinElmer’s NexION 2000 Single Cell ICP-MS has the ability to detect metal in a single ovarian cancer cell, which will lead to new cancer strategies and therapies.
Researchers have developed an optimized and validated routine method for collecting stool samples to extract DNA for the first time. The method uses PerkinElmer's chemagic MSM I extraction instrument and is expected to accelerate microbiome research.
A new generation of high-content imaging systems such as the PerkinElmer Operetta CLS High Content Imaging System and Harmony High Content Imaging and Analysis Software are helping scientists to blaze new trails in cancer drug therapy.